Onyx Pharmaceuticals Announces Carfilzomib Development and Commercialization Agreement with Ono Pharmaceutical for Japan

8 September 2010, 4:14 am

EMERYVILLE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and ...... Read More »

More Topics from "Articles"

• GeckoSystems Signs Manufacturing Contract to Expand Elder Care Robot Trials
• Consortium of ADHD Organizations Join Forces for ADHD Awareness Week, September 13-17
• Calcuccino Lite - The Free Programmers' Calculator For The iPhone
• Peter Lehner: The Media, Climate Science, and Deniers: Time to Tell a New Story
• Use of informatics, EMRs enable genetic study of vascular disease
• Enablence Unveils New 10G APD Photodiode and 8x8 Multicast Switch at Europe's Top Optical Communications Event
• Press Release
• NASA Team to Trapped Miners: No Alcohol or Cigarettes
• Surinder Sud: Farming without fear